Additional exclusivity is provided for the company’s HspE7 investigational therapeutic vaccine.

Nventa Biopharmaceuticals was issued a patent for compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant. The company’s CoVal™ HPV protein fusions are being developed to treat patients with HPV-related diseases.


The patent provides for a method of treating a tumor expressing an HPV antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein, according to Gregory M. McKee, president and CEO of Nventa. This patent provides additional patent exclusivity for HspE7, the Company’s investigational therapeutic vaccine, and future HPV fusions through February 2019.


“The issuance of this patent protecting the use of our HPV CoVal protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase I clinical development,” says McKee.

Previous articleFDA Approves Genzyme’s Epicel
Next articleAstraZeneca Consolidates Biologics Businesses